Cathelicidin-encoding Lactococcus lactis promotes mucosal repair in murine experimental colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 3, 2017, Pages 609-619

  Wong, Clover C M ^a   Zhang, Lin ^a,b   Wu, William K K ^b   Shen, Jing ^c   Chan, Ruby L Y ^a   Lu, Lan ^d   Hu, Wei ^a   Li, Ming X ^c   Li, Long F ^c   Ren, Shun X ^a   Li, Yi F ^e   Li, Jiang ^e   Cho, Chi H ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

^d CHENGDU UNIVERSITY   (China)

^e The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

Author keywords

cathelicidin; experimental colitis; Lactococcus lactis

Indexed keywords

CATHELICIDIN; CATHELICIDIN ENCODING LACTOCOCCUS LACTIS; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CRYPT CELL; EXPERIMENTAL ULCERATIVE COLITIS; GASTROINTESTINAL HEMORRHAGE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LACTOCOCCUS LACTIS; MALE; MOUSE; NONHUMAN; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; COLITIS, ULCERATIVE; COLON; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; INTESTINE MUCOSA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLITIS, ULCERATIVE; COLON; EPITHELIAL CELLS; INTESTINAL MUCOSA; LACTOCOCCUS LACTIS; MALE; MICE, INBRED BALB C; WOUND HEALING;

EID: 85015896919     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13499     Document Type: Article

References (26)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 2006; 12: S3–9.
2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 331–340.
3. Agerberth B, Charo J, Werr J et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96: 3086–3093.
4. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 9541–9546.
5. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect. Immun. 2002; 70: 953–963.
6. Podolsky DK. Review article: healing after inflammatory injury—coordination of a regulatory peptide network. Aliment. Pharmacol. Ther. 2000; 14 (Suppl 1): 87–93.
7. Heilborn JD, Nilsson MF, Kratz G et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 2003; 120: 379–389.
8. Tokumaru S, Sayama K, Shirakata Y et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. 2005; 175: 4662–4668.
9. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 289: L842–848.
10. Yang YH, Wu WK, Tai EK et al. The cationic host defense peptide rCRAMP promotes gastric ulcer healing in rats. J. Pharmacol. Exp. Ther. 2006; 318: 547–554.
11. Specian RD, Oliver MG. Functional biology of intestinal goblet cells. Am. J. Physiol. 1991; 260: C183–193.
12. Pullan RD, Thomas GA, Rhodes M et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994; 35: 353–359.
13. Strugala V, Dettmar PW, Pearson JP. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int. J. Clin. Pract. 2008; 62: 762–769.
14. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 15064–15069.
15. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp. Biol. Med. (Maywood) 2007; 232: 799–808.
16. Tai EK, Wong HP, Lam EK et al. Cathelicidin stimulates colonic mucus synthesis by up-regulating MUC1 and MUC2 expression through a mitogen-activated protein kinase pathway. J. Cell. Biochem. 2008; 104 (1): 251–258.
17. Wong CC, Zhang L, Li ZJ et al. Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. J. Gastroenterol. Hepatol. 2012; 27: 1205–1212.
18. Liu ES, Ye YN, Shin VY et al. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis 2003; 24: 1407–1413.
19. Holo H, Nes IF. High-frequency transformation, by electroporation, of Lactococcus lactis subsp. Cremoris grown with glycine in osmotically stabilized media. Appl. Environ. Microbiol. 1989; 55: 3119–3123.
20. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993; 69: 238–249.
21. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992; 119: 493–501.
22. Tarnawski A, Stachura J, Durbin T, Sarfeh IJ, Gergely H. Increased expression of epidermal growth factor receptor during gastric ulcer healing in rats. Gastroenterology 1992; 102: 695–698.
23. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2007; 2: 329–333.
24. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641–1657.
25. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68–82.
26. Hassaing B, Aitken JD, Malleshappa M, Kumar MV. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2014; 104: Unit-15.25.